Enveric Biosciences, Inc. (ENVB)
1.46
+0.04
(+2.82%)
USD |
NASDAQ |
Oct 28, 11:24
Enveric Biosciences Enterprise Value : -2.707M for Oct. 27, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 27, 2026 | -2.707M |
| October 26, 2026 | -2.865M |
| October 23, 2026 | -2.786M |
| October 22, 2026 | -2.550M |
| October 21, 2026 | -2.353M |
| October 20, 2026 | -2.629M |
| October 19, 2026 | -2.825M |
| October 16, 2026 | -2.865M |
| October 15, 2026 | -2.825M |
| October 14, 2026 | -2.904M |
| October 13, 2026 | -2.786M |
| October 12, 2026 | -2.510M |
| October 09, 2026 | -2.589M |
| October 08, 2026 | -2.314M |
| October 07, 2026 | -2.412M |
| October 06, 2026 | -2.510M |
| October 05, 2026 | -2.353M |
| October 02, 2026 | -2.471M |
| October 01, 2026 | -2.550M |
| September 30, 2026 | -2.452M |
| September 29, 2026 | -2.589M |
| September 28, 2026 | -2.510M |
| September 25, 2026 | -2.392M |
| September 24, 2026 | -2.215M |
| September 23, 2026 | -2.137M |
| Date | Value |
|---|---|
| September 22, 2026 | -2.235M |
| September 21, 2026 | -2.156M |
| September 18, 2026 | -1.920M |
| September 17, 2026 | -2.038M |
| September 16, 2026 | -2.432M |
| September 15, 2026 | -2.550M |
| September 14, 2026 | -2.471M |
| September 11, 2026 | -2.707M |
| September 10, 2026 | -2.550M |
| September 09, 2026 | -2.570M |
| September 08, 2026 | -2.707M |
| September 04, 2026 | -2.825M |
| September 03, 2026 | -2.629M |
| September 02, 2026 | -2.629M |
| September 01, 2026 | -2.904M |
| August 31, 2026 | -2.904M |
| August 28, 2026 | -2.904M |
| August 27, 2026 | -2.904M |
| August 26, 2026 | -2.904M |
| August 25, 2026 | -2.550M |
| August 24, 2026 | -2.747M |
| August 21, 2026 | -2.668M |
| August 20, 2026 | -2.825M |
| August 19, 2026 | -3.140M |
| August 18, 2026 | -2.983M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| LENZ Therapeutics, Inc. | -120.47M |
| Impact BioMedical, Inc. | 33.57M |
| ANI Pharmaceuticals, Inc. | 1.870B |
| Corcept Therapeutics, Inc. | 9.154B |
| Veru, Inc. | 15.77M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.028M |
| Total Expenses (Quarterly) | 3.028M |
| EPS Diluted (Quarterly) | -0.7594 |
| Earnings Yield | -1.13K% |
| Normalized Earnings Yield | -1127.39 |